Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of IBI128 (Tigulixostat) in Chinese Gout Subjects
NCT06501534Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tigulixostat in gout, sponsored by Innovent Biologics. Started Jul 2024; status: completed.
02
Drugs
tigulixostat
03
Conditions
gout
Beyond the preview
Go deeper on NCT06501534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501534.